{"transactions":[{"id":963454,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T15:34:54.000Z","date":"2025-12-16","kind":"sale","planned":false,"acquired":false,"shares":30681,"price":6.66,"value":204335.46,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold in multiple transactions at prices ranging from $6.64 to $6.69. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5614457,"source":{"system":"sec-edgar","filing":"0001493152-25-028303","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315225028303/ownership.xml","form_type":"4"}},{"id":963453,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T15:34:54.000Z","date":"2025-11-24","kind":"other","planned":false,"acquired":false,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5645138,"source":{"system":"sec-edgar","filing":"0001493152-25-028303","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315225028303/ownership.xml","form_type":"4"}},{"id":978018,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-08T18:21:15.000Z","date":"2025-12-03","kind":"sale","planned":false,"acquired":false,"shares":132069,"price":5.73,"value":756755.37,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold in multiple transactions at prices ranging from $5.68 to $5.85. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5670138,"source":{"system":"sec-edgar","filing":"0001493152-25-026587","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315225026587/ownership.xml","form_type":"4/A","original_submission_date":"2025-12-04"}},{"id":978017,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-08T18:21:15.000Z","date":"2025-12-02","kind":"sale","planned":false,"acquired":false,"shares":30000,"price":5.47,"value":164100.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $5.40 to $5.50. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5802207,"source":{"system":"sec-edgar","filing":"0001493152-25-026587","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315225026587/ownership.xml","form_type":"4/A","original_submission_date":"2025-12-04"}},{"id":980571,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-04T21:57:00.000Z","date":"2025-12-03","kind":"sale","planned":false,"acquired":false,"shares":120000,"price":5.73,"value":687600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold in multiple transactions at prices ranging from $5.68 to $5.85. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5682207,"source":{"system":"sec-edgar","filing":"0001493152-25-026204","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315225026204/ownership.xml","form_type":"4"}},{"id":980570,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-04T21:57:00.000Z","date":"2025-12-02","kind":"sale","planned":false,"acquired":false,"shares":30000,"price":5.47,"value":164100.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $5.40 to $5.50. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5802207,"source":{"system":"sec-edgar","filing":"0001493152-25-026204","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315225026204/ownership.xml","form_type":"4"}},{"id":1002551,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-12T21:33:48.000Z","date":"2025-11-11","kind":"sale","planned":false,"acquired":false,"shares":40000,"price":5.25,"value":210000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5832207,"source":{"system":"sec-edgar","filing":"0001493152-25-021959","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315225021959/ownership.xml","form_type":"4"}},{"id":1013943,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-25T00:18:00.000Z","date":"2025-10-22","kind":"sale","planned":false,"acquired":false,"shares":30000,"price":4.94,"value":148200.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5872207,"source":{"system":"sec-edgar","filing":"0001493152-25-019379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315225019379/ownership.xml","form_type":"4"}},{"id":1013942,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-25T00:18:00.000Z","date":"2025-10-22","kind":"sale","planned":false,"acquired":false,"shares":20000,"price":4.93,"value":98600.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5902207,"source":{"system":"sec-edgar","filing":"0001493152-25-019379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315225019379/ownership.xml","form_type":"4"}},{"id":1115413,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Stock options were exercisable at time of exercise."}],"balance_after":0,"derivative":{"exercise_price":1.11,"expiration_date":"2025-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115412,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Stock options were exercisable at time of exercise."}],"balance_after":40000,"derivative":{"exercise_price":1.98,"expiration_date":"2025-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115411,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":false,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Stock options were exercisable at time of exercise."}],"balance_after":80000,"derivative":{"exercise_price":2.11,"expiration_date":"2025-06-07","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115410,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Stock options were exercisable at time of exercise."}],"balance_after":150000,"derivative":{"exercise_price":2.11,"expiration_date":"2025-06-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115409,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Stock options were exercisable at time of exercise."}],"balance_after":190000,"derivative":{"exercise_price":2.86,"expiration_date":"2025-06-07","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115408,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Stock options were exercisable at time of exercise."}],"balance_after":220000,"derivative":{"exercise_price":4.72,"expiration_date":"2025-06-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115407,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":false,"shares":46875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Stock options were exercisable at time of exercise."}],"balance_after":245000,"derivative":{"exercise_price":2.39,"expiration_date":"2025-06-07","underlying":"Common Stock","underlying_shares":46875},"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115406,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":false,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Stock options were exercisable at time of exercise."}],"balance_after":291875,"derivative":{"exercise_price":0.89,"expiration_date":"2025-06-07","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115405,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":1.11,"value":44400.0,"ownership":{"direct":true},"balance_after":1045541,"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115404,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":1.98,"value":79200.0,"ownership":{"direct":true},"balance_after":1005541,"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115403,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":true,"shares":70000,"price":2.11,"value":147700.0,"ownership":{"direct":true},"balance_after":965541,"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115402,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":2.11,"value":84400.0,"ownership":{"direct":true},"balance_after":895541,"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115401,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":2.86,"value":85800.0,"ownership":{"direct":true},"balance_after":855541,"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115400,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":true,"shares":25000,"price":4.72,"value":118000.0,"ownership":{"direct":true},"balance_after":825541,"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115399,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":true,"shares":46875,"price":2.39,"value":112031.25,"ownership":{"direct":true},"balance_after":800541,"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115398,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T22:25:16.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":true,"shares":31250,"price":0.89,"value":27812.5,"ownership":{"direct":true},"balance_after":753666,"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115397,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T22:25:16.000Z","date":"2025-03-31","kind":"other","planned":false,"acquired":true,"shares":1000,"price":6,"value":6000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividend was paid on 3/31/2025. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividend was paid on 3/31/2025. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."}],"balance_after":722416,"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115396,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T22:25:16.000Z","date":"2025-02-04","kind":"gift","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"No consideration was received for the shares, which were transferred by gift to relatives."}],"balance_after":721416,"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115395,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T22:25:16.000Z","date":"2025-02-03","kind":"gift","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"No consideration was received for the shares, which were transferred by gift to relatives."}],"balance_after":731416,"source":{"system":"sec-edgar","filing":"0001641172-25-014756","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014756/ownership.xml","form_type":"4"}},{"id":1115394,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T21:18:21.000Z","date":"2024-12-19","kind":"gift","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"No consideration was received for the shares, which were transferred by gift to relatives."}],"balance_after":741416,"source":{"system":"sec-edgar","filing":"0001641172-25-014742","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014742/ownership.xml","form_type":"5"}},{"id":1115393,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T21:18:21.000Z","date":"2024-07-03","kind":"gift","planned":false,"acquired":false,"shares":600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"No consideration was received for the shares, which were transferred by gift to relatives."}],"balance_after":746416,"source":{"system":"sec-edgar","filing":"0001641172-25-014742","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014742/ownership.xml","form_type":"5"}},{"id":1115392,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T21:18:21.000Z","date":"2024-09-30","kind":"other","planned":false,"acquired":true,"shares":1000,"price":6,"value":6000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2024 and 9/30/2024. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2024 and 9/30/2024. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."}],"balance_after":747016,"source":{"system":"sec-edgar","filing":"0001641172-25-014742","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014742/ownership.xml","form_type":"5"}},{"id":1115391,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T21:18:21.000Z","date":"2024-06-26","kind":"gift","planned":false,"acquired":false,"shares":4400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"No consideration was received for the shares, which were transferred by gift to relatives."}],"balance_after":746016,"source":{"system":"sec-edgar","filing":"0001641172-25-014742","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014742/ownership.xml","form_type":"5"}},{"id":1115390,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T21:18:21.000Z","date":"2024-05-17","kind":"gift","planned":false,"acquired":false,"shares":4400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"No consideration was received for the shares, which were transferred by gift to relatives."}],"balance_after":750416,"source":{"system":"sec-edgar","filing":"0001641172-25-014742","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014742/ownership.xml","form_type":"5"}},{"id":1115389,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T21:18:21.000Z","date":"2024-05-17","kind":"gift","planned":false,"acquired":false,"shares":4400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"No consideration was received for the shares, which were transferred by gift to relatives."}],"balance_after":754816,"source":{"system":"sec-edgar","filing":"0001641172-25-014742","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014742/ownership.xml","form_type":"5"}},{"id":1115388,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T21:18:21.000Z","date":"2024-05-10","kind":"gift","planned":false,"acquired":false,"shares":4400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"No consideration was received for the shares, which were transferred by gift to relatives."}],"balance_after":759216,"source":{"system":"sec-edgar","filing":"0001641172-25-014742","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014742/ownership.xml","form_type":"5"}},{"id":1115387,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T21:18:21.000Z","date":"2024-03-31","kind":"other","planned":false,"acquired":true,"shares":1000,"price":6,"value":6000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2024 and 9/30/2024. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2024 and 9/30/2024. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."}],"balance_after":763616,"source":{"system":"sec-edgar","filing":"0001641172-25-014742","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000164117225014742/ownership.xml","form_type":"5"}},{"id":1535572,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-25T15:37:35.000Z","date":"2023-09-30","kind":"other","planned":false,"acquired":true,"shares":1000,"price":6,"value":6000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."}],"balance_after":762616,"source":{"system":"sec-edgar","filing":"0001493152-24-015879","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315224015879/ownership.xml","form_type":"5"}},{"id":1535571,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-25T15:37:35.000Z","date":"2023-03-31","kind":"other","planned":false,"acquired":true,"shares":1000,"price":6,"value":6000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."}],"balance_after":761616,"source":{"system":"sec-edgar","filing":"0001493152-24-015879","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315224015879/ownership.xml","form_type":"5"}},{"id":1535570,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-25T15:36:44.000Z","date":"2024-04-23","kind":"sale","planned":false,"acquired":false,"shares":3677,"price":3.06,"value":11251.62,"ownership":{"direct":false,"nature":"By 10X Fund, LP"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities were sold by 10X Fund, LP. James C. Czirr is the manager of 10X Capital Management, LLC, which is the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such Mr. Czirr may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5922207,"source":{"system":"sec-edgar","filing":"0001493152-24-015877","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315224015877/ownership.xml","form_type":"4"}},{"id":1535569,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-25T15:36:44.000Z","date":"2024-04-22","kind":"sale","planned":false,"acquired":false,"shares":21323,"price":3.06,"value":65248.38,"ownership":{"direct":false,"nature":"By 10X Fund, LP"},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities were sold by 10X Fund, LP. James C. Czirr is the manager of 10X Capital Management, LLC, which is the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such Mr. Czirr may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5925884,"source":{"system":"sec-edgar","filing":"0001493152-24-015877","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315224015877/ownership.xml","form_type":"4"}},{"id":1725768,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T21:50:50.000Z","date":"2022-09-30","kind":"other","planned":false,"acquired":true,"shares":1000,"price":6,"value":6000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."}],"balance_after":760616,"source":{"system":"sec-edgar","filing":"0001493152-23-043431","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315223043431/ownership.xml","form_type":"5"}},{"id":1725767,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T21:50:50.000Z","date":"2022-03-31","kind":"other","planned":false,"acquired":true,"shares":1000,"price":6,"value":6000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2020 and 9/30/2020. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."}],"balance_after":760616,"source":{"system":"sec-edgar","filing":"0001493152-23-043431","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315223043431/ownership.xml","form_type":"5"}},{"id":1725766,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T21:50:50.000Z","date":"2022-01-12","kind":"gift","planned":false,"acquired":false,"shares":4500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares transferred to child as a gift. Transaction does not constitute a sale pursuant to Rule 16a-5."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares transferred to child as a gift. Transaction does not constitute a sale pursuant to Rule 16a-5."}],"balance_after":760616,"source":{"system":"sec-edgar","filing":"0001493152-23-043431","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315223043431/ownership.xml","form_type":"5"}},{"id":1725765,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T21:50:50.000Z","date":"2022-01-12","kind":"gift","planned":false,"acquired":false,"shares":4500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares transferred to child as a gift. Transaction does not constitute a sale pursuant to Rule 16a-5."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares transferred to child as a gift. Transaction does not constitute a sale pursuant to Rule 16a-5."}],"balance_after":760616,"source":{"system":"sec-edgar","filing":"0001493152-23-043431","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315223043431/ownership.xml","form_type":"5"}},{"id":1725764,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-01T21:50:50.000Z","date":"2022-01-12","kind":"gift","planned":false,"acquired":false,"shares":4500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares transferred to child as a gift. Transaction does not constitute a sale pursuant to Rule 16a-5."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares transferred to child as a gift. Transaction does not constitute a sale pursuant to Rule 16a-5."}],"balance_after":760616,"source":{"system":"sec-edgar","filing":"0001493152-23-043431","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315223043431/ownership.xml","form_type":"5"}},{"id":2040549,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-31T19:51:56.000Z","date":"2022-12-21","kind":"other","acquired":false,"shares":61407,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5947207,"source":{"system":"sec-edgar","filing":"0001493152-23-003128","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315223003128/ownership.xml","form_type":"5"}},{"id":2040548,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-31T19:51:56.000Z","date":"2022-12-21","kind":"other","acquired":false,"shares":3077,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6008614,"source":{"system":"sec-edgar","filing":"0001493152-23-003128","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315223003128/ownership.xml","form_type":"5"}},{"id":2040547,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-31T19:51:56.000Z","date":"2022-12-21","kind":"other","acquired":false,"shares":16050,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6011691,"source":{"system":"sec-edgar","filing":"0001493152-23-003128","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315223003128/ownership.xml","form_type":"5"}},{"id":2040546,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-31T19:51:56.000Z","date":"2022-12-21","kind":"other","acquired":false,"shares":17117,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6027741,"source":{"system":"sec-edgar","filing":"0001493152-23-003128","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315223003128/ownership.xml","form_type":"5"}},{"id":2040545,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-31T19:51:56.000Z","date":"2022-07-29","kind":"other","acquired":false,"shares":90586,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6044858,"source":{"system":"sec-edgar","filing":"0001493152-23-003128","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315223003128/ownership.xml","form_type":"5"}},{"id":2040544,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-31T19:51:56.000Z","date":"2022-07-29","kind":"other","acquired":false,"shares":33496,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his/her/its pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6135444,"source":{"system":"sec-edgar","filing":"0001493152-23-003128","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315223003128/ownership.xml","form_type":"5"}},{"id":2042449,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-01-30T21:35:03.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2023."}],"balance_after":40000,"derivative":{"exercise_price":1.11,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001133416-23-000010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000010/form4.xml","form_type":"4"}},{"id":2191208,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-09T19:01:58.000Z","date":"2022-07-22","kind":"sale","acquired":false,"shares":10000,"price":2.087,"value":20870.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6168940,"source":{"system":"sec-edgar","filing":"0001493152-22-021740","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315222021740/ownership.xml","form_type":"4"}},{"id":2411895,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-04T23:23:24.000Z","date":"2022-02-02","kind":"sale","acquired":false,"shares":10000,"price":2.1,"value":21000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6178940,"source":{"system":"sec-edgar","filing":"0001493152-22-003302","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315222003302/ownership.xml","form_type":"4"}},{"id":2426935,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-01-25T21:42:22.000Z","date":"2022-01-24","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2022."}],"balance_after":40000,"derivative":{"exercise_price":1.98,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001133416-22-000033","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000033/form4.xml","form_type":"4"}},{"id":2436127,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-13T20:42:07.000Z","date":"2022-01-11","kind":"sale","acquired":false,"shares":10000,"price":2.1,"value":21000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6188940,"source":{"system":"sec-edgar","filing":"0001493152-22-001148","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315222001148/ownership.xml","form_type":"4"}},{"id":2484098,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-06T17:42:51.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":10000,"price":2.37,"value":23700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6198940,"source":{"system":"sec-edgar","filing":"0001493152-21-030546","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221030546/ownership.xml","form_type":"4"}},{"id":2524857,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-04T15:55:59.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":10000,"price":3.19,"value":31900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6208940,"source":{"system":"sec-edgar","filing":"0001493152-21-027207","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221027207/ownership.xml","form_type":"4"}},{"id":2539647,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-19T19:18:14.000Z","date":"2021-10-15","kind":"sale","acquired":false,"shares":10000,"price":3.37,"value":33700.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6218940,"source":{"system":"sec-edgar","filing":"0001493152-21-025776","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221025776/ownership.xml","form_type":"4"}},{"id":2547430,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-06T16:00:47.000Z","date":"2021-10-04","kind":"sale","acquired":false,"shares":10000,"price":3.62,"value":36200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6228940,"source":{"system":"sec-edgar","filing":"0001493152-21-024757","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221024757/ownership.xml","form_type":"4"}},{"id":2579872,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T13:00:28.000Z","date":"2021-09-01","kind":"sale","acquired":false,"shares":10000,"price":3.91,"value":39100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6238940,"source":{"system":"sec-edgar","filing":"0001493152-21-021935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221021935/ownership.xml","form_type":"4"}},{"id":2618264,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":2,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":3,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T19:48:36.000Z","date":"2021-08-02","kind":"sale","acquired":false,"shares":10000,"price":3.25,"value":32500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6248940,"source":{"system":"sec-edgar","filing":"0001493152-21-018420","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221018420/ownership.xml","form_type":"4"}},{"id":2633325,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":2,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":3,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-15T18:27:45.000Z","date":"2021-07-09","kind":"sale","acquired":false,"shares":10000,"price":3.54,"value":35400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6258940,"source":{"system":"sec-edgar","filing":"0001493152-21-016934","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221016934/ownership.xml","form_type":"4"}},{"id":2684011,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-03T21:27:17.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":10000,"price":3.91,"value":39100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6268940,"source":{"system":"sec-edgar","filing":"0001493152-21-013547","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221013547/ownership.xml","form_type":"4"}},{"id":2727780,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-05T16:05:49.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":10000,"price":3.84,"value":38400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6278940,"source":{"system":"sec-edgar","filing":"0001493152-21-010480","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221010480/ownership.xml","form_type":"4/A","original_submission_date":"2021-05-04"}},{"id":2727779,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-05T16:05:49.000Z","date":"2021-04-28","kind":"sale","acquired":false,"shares":10000,"price":5.02,"value":50200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6288940,"source":{"system":"sec-edgar","filing":"0001493152-21-010480","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221010480/ownership.xml","form_type":"4/A","original_submission_date":"2021-05-04"}},{"id":2727778,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-05T16:05:49.000Z","date":"2021-04-26","kind":"sale","acquired":false,"shares":7500,"price":4.47,"value":33525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6298940,"source":{"system":"sec-edgar","filing":"0001493152-21-010480","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221010480/ownership.xml","form_type":"4/A","original_submission_date":"2021-05-04"}},{"id":2727777,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-05T16:05:49.000Z","date":"2021-04-23","kind":"sale","acquired":false,"shares":5000,"price":3.95,"value":19750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6306440,"source":{"system":"sec-edgar","filing":"0001493152-21-010480","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221010480/ownership.xml","form_type":"4/A","original_submission_date":"2021-05-04"}},{"id":2727776,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-05T16:05:49.000Z","date":"2021-04-22","kind":"sale","acquired":false,"shares":5000,"price":3.52,"value":17600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6311440,"source":{"system":"sec-edgar","filing":"0001493152-21-010480","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221010480/ownership.xml","form_type":"4/A","original_submission_date":"2021-05-04"}},{"id":2730800,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T20:52:48.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":10000,"price":3.84,"value":38400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6288940,"source":{"system":"sec-edgar","filing":"0001493152-21-010442","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221010442/ownership.xml","form_type":"4"}},{"id":2730799,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T20:52:48.000Z","date":"2021-04-26","kind":"sale","acquired":false,"shares":7500,"price":4.47,"value":33525.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6298940,"source":{"system":"sec-edgar","filing":"0001493152-21-010442","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221010442/ownership.xml","form_type":"4"}},{"id":2730798,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T20:52:48.000Z","date":"2021-04-23","kind":"sale","acquired":false,"shares":5000,"price":3.95,"value":19750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6306440,"source":{"system":"sec-edgar","filing":"0001493152-21-010442","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221010442/ownership.xml","form_type":"4"}},{"id":2730797,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T20:52:48.000Z","date":"2021-04-22","kind":"sale","acquired":false,"shares":5000,"price":3.52,"value":17600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6311440,"source":{"system":"sec-edgar","filing":"0001493152-21-010442","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221010442/ownership.xml","form_type":"4"}},{"id":2758514,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-05T17:48:57.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":10000,"price":2.16,"value":21600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6316440,"source":{"system":"sec-edgar","filing":"0001493152-21-007950","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221007950/ownership.xml","form_type":"4"}},{"id":2769601,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-03-29T20:35:42.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results."}],"balance_after":70000,"derivative":{"exercise_price":2.11,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000899243-21-013815","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924321013815/doc4.xml","form_type":"4"}},{"id":2769600,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-03-29T20:35:42.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such options vest 100% on March 31, 2022."}],"balance_after":40000,"derivative":{"exercise_price":2.11,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-21-013815","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924321013815/doc4.xml","form_type":"4"}},{"id":2809327,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-03-04T21:06:22.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":10000,"price":2.31,"value":23100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6326440,"source":{"system":"sec-edgar","filing":"0001493152-21-005375","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221005375/ownership.xml","form_type":"4"}},{"id":2876944,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-02-05T15:47:48.000Z","date":"2021-02-02","kind":"sale","acquired":false,"shares":10000,"price":2.04,"value":20400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6336440,"source":{"system":"sec-edgar","filing":"0001493152-21-002719","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221002719/ownership.xml","form_type":"4"}},{"id":2921741,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-05T22:36:46.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":10000,"price":2.23,"value":22300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold pursuant to 10X Fund, LP's Rule 10b5-1 trading plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6346440,"source":{"system":"sec-edgar","filing":"0001493152-21-000241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315221000241/ownership.xml","form_type":"4"}},{"id":3006434,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":2,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":3,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-15T21:03:34.000Z","date":"2020-10-13","kind":"sale","acquired":false,"shares":10000,"price":2.97,"value":29700.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6356440,"source":{"system":"sec-edgar","filing":"0001493152-20-019507","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315220019507/ownership.xml","form_type":"4"}},{"id":3274599,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-13T21:59:27.000Z","date":"2019-10-23","kind":"other","acquired":false,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Shares transferred to ex-spouse pursuant to a divorce decree. Transaction does not constitute a sale pursuant to existing court rulings and SEC interpretative guidance."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Amount beneficially owned is different from prior reports by 14 shares as a result of the erroneous reporting in Form 5 for 2018 fiscal year of the receipt of 1,000 shares as a stock dividend on Series A Convertible Stock on September 30, 2018. Mr. Czirr, actually received 986 as a stock dividend."}],"balance_after":767616,"source":{"system":"sec-edgar","filing":"0001493152-20-002229","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315220002229/ownership.xml","form_type":"5"}},{"id":3274598,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-13T21:59:27.000Z","date":"2019-09-30","kind":"other","acquired":true,"shares":1000,"price":6,"value":6000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 9/30/2019. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9 and as an involuntary transaction pursuant to court decisions."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 9/30/2019. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount beneficially owned is different from prior reports by 14 shares as a result of the erroneous reporting in Form 5 for 2018 fiscal year of the receipt of 1,000 shares as a stock dividend on Series A Convertible Stock on September 30, 2018. Mr. Czirr, actually received 986 as a stock dividend."}],"balance_after":892616,"source":{"system":"sec-edgar","filing":"0001493152-20-002229","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315220002229/ownership.xml","form_type":"5"}},{"id":3274597,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-13T21:35:03.000Z","date":"2019-11-18","kind":"other","acquired":false,"shares":9350,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6366440,"source":{"system":"sec-edgar","filing":"0001493152-20-002223","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315220002223/ownership.xml","form_type":"5"}},{"id":3306625,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-01-21T21:54:09.000Z","date":"2020-01-17","kind":"sale","acquired":false,"shares":10000,"price":2.97,"value":29700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold pursuant to 10X Fund, LP's Quarterly Liquidity Program."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6375790,"source":{"system":"sec-edgar","filing":"0001493152-20-000877","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315220000877/ownership.xml","form_type":"4"}},{"id":3312687,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-01-13T23:02:10.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on December 31, 2020."}],"balance_after":30000,"derivative":{"exercise_price":2.86,"expiration_date":"2030-01-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-20-001120","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924320001120/doc4.xml","form_type":"4"}},{"id":3393796,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"General partner"}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member of GP"}}],"security":"Common Stock","published_at":"2019-10-15T10:56:18.000Z","date":"2019-10-10","kind":"sale","acquired":false,"shares":17000,"price":3.725,"value":63325.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold pursuant to 10X Fund, LP's Quarterly Liquidity Program."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6385790,"source":{"system":"sec-edgar","filing":"0001493152-19-015454","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315219015454/ownership.xml","form_type":"4"}},{"id":3393795,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"General partner"}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member of GP"}}],"security":"Common Stock","published_at":"2019-10-15T10:56:18.000Z","date":"2019-08-02","kind":"other","acquired":false,"shares":38690,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security pursuant to applicable law."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6402790,"source":{"system":"sec-edgar","filing":"0001493152-19-015454","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315219015454/ownership.xml","form_type":"4"}},{"id":3456160,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"General partner"}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member of GP"}}],"security":"Common Stock","published_at":"2019-07-25T10:03:45.000Z","date":"2019-07-15","kind":"other","acquired":false,"shares":306,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security pursuant to applicable law."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security pursuant to applicable law."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6441480,"source":{"system":"sec-edgar","filing":"0001493152-19-011073","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315219011073/ownership.xml","form_type":"4"}},{"id":3492963,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"General Partner"}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member of GP"}}],"security":"Common Stock","published_at":"2019-06-12T17:13:23.000Z","date":"2019-05-03","kind":"other","acquired":false,"shares":67515,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares were distributed in an in-kind distribution to a withdrawing limited partner of 10X Fund, LP of his pro rata share of shares held by 10X Fund, LP, which did not receive any consideration for the transfer. The distribution is exempt from Section 16(b) because it does not constitute a sale of a security under applicable law."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":6441786,"source":{"system":"sec-edgar","filing":"0001493152-19-009040","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315219009040/ownership.xml","form_type":"4"}},{"id":3569348,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-02T12:45:26.000Z","date":"2018-09-30","kind":"other","acquired":true,"shares":1000,"price":6,"value":6000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2018 and 9/30/2018. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9 and as an involuntary transaction pursuant to court decisions."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2018 and 9/30/2018. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."}],"balance_after":891630,"source":{"system":"sec-edgar","filing":"0001493152-19-004665","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315219004665/ownership.xml","form_type":"5"}},{"id":3569347,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":1,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-02T12:45:26.000Z","date":"2018-03-31","kind":"other","acquired":true,"shares":1000,"price":6,"value":6000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2018 and 9/30/2018. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9 and as an involuntary transaction pursuant to court decisions."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2018 and 9/30/2018. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."}],"balance_after":890630,"source":{"system":"sec-edgar","filing":"0001493152-19-004665","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315219004665/ownership.xml","form_type":"5"}},{"id":3572559,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"General Partner"}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member of GP"}}],"security":"Common Stock","published_at":"2019-04-01T22:02:42.000Z","date":"2018-09-30","kind":"other","acquired":true,"shares":38144,"price":6.03,"value":230008.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Common stock received in satisfaction of $230,160 of dividends due on Series B-1, B-2 and B-3 Convertible Preferred Stock owned by 10X Fund, L.P. pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividend was payable on 9/30/2018. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9 and as an involuntary transaction pursuant to court decisions."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Common stock received in satisfaction of $230,160 of dividends due on Series B-1, B-2 and B-3 Convertible Preferred Stock owned by 10X Fund, L.P. pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividend was payable on 9/30/2018. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":2719955,"source":{"system":"sec-edgar","filing":"0001493152-19-004632","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315219004632/ownership.xml","form_type":"5"}},{"id":3572558,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"General Partner"}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member of GP"}}],"security":"Common Stock","published_at":"2019-04-01T22:02:42.000Z","date":"2018-06-30","kind":"other","acquired":true,"shares":31606,"price":7.28,"value":230091.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Common stock received in satisfaction of $230,160 of dividends due on Series B-1, B-2 and B-3 Convertible Preferred Stock owned by 10X Fund, L.P. pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividend was payable on 6/30/2018. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9 and as an involuntary transaction pursuant to court decisions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Common stock received in satisfaction of $230,160 of dividends due on Series B-1, B-2 and B-3 Convertible Preferred Stock owned by 10X Fund, L.P. pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividend was payable on 6/30/2018. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":2681811,"source":{"system":"sec-edgar","filing":"0001493152-19-004632","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315219004632/ownership.xml","form_type":"5"}},{"id":3572557,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"General Partner"}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member of GP"}}],"security":"Common Stock","published_at":"2019-04-01T22:02:42.000Z","date":"2018-03-31","kind":"other","acquired":true,"shares":48802,"price":4.72,"value":230345.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Common stock received in satisfaction of $230,160 of dividends due on Series B-1, B-2 and B-3 Convertible Preferred Stock owned by 10X Fund, L.P. pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividend was payable on 3/31/2018. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9 and as an involuntary transaction pursuant to court decisions."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Common stock received in satisfaction of $230,160 of dividends due on Series B-1, B-2 and B-3 Convertible Preferred Stock owned by 10X Fund, L.P. pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividend was payable on 3/31/2018. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":3170205,"source":{"system":"sec-edgar","filing":"0001493152-19-004632","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315219004632/ownership.xml","form_type":"5"}},{"id":3572556,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"General Partner"}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member of GP"}}],"security":"Series B-3 Preferred Stock","published_at":"2019-04-01T21:59:32.000Z","date":"2019-01-11","kind":"exercise","acquired":false,"shares":1008000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":1.1238,"underlying":"Common Stock","underlying_shares":896997},"source":{"system":"sec-edgar","filing":"0001493152-19-004630","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315219004630/ownership.xml","form_type":"4"}},{"id":3572555,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"General Partner"}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member of GP"}}],"security":"Series B-3 Preferred Stock","published_at":"2019-04-01T21:59:32.000Z","date":"2019-01-11","kind":"exercise","acquired":false,"shares":1125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":1.4938,"underlying":"Common Stock","underlying_shares":753138},"source":{"system":"sec-edgar","filing":"0001493152-19-004630","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315219004630/ownership.xml","form_type":"4"}},{"id":3572554,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"General Partner"}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member of GP"}}],"security":"Series B-3 Preferred Stock","published_at":"2019-04-01T21:59:32.000Z","date":"2019-01-11","kind":"exercise","acquired":false,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":2.6938,"underlying":"Common Stock","underlying_shares":139211},"source":{"system":"sec-edgar","filing":"0001493152-19-004630","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315219004630/ownership.xml","form_type":"4"}},{"id":3572553,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"General Partner"}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member of GP"}}],"security":"Series B-2 Preferred Stock","published_at":"2019-04-01T21:59:32.000Z","date":"2019-01-11","kind":"exercise","acquired":false,"shares":285000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":3,"underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001493152-19-004630","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315219004630/ownership.xml","form_type":"4"}},{"id":3572552,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"General Partner"}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member of GP"}}],"security":"Series B-2 Preferred Stock","published_at":"2019-04-01T21:59:32.000Z","date":"2019-01-11","kind":"exercise","acquired":false,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":3,"underlying":"Common Stock","underlying_shares":103333},"source":{"system":"sec-edgar","filing":"0001493152-19-004630","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315219004630/ownership.xml","form_type":"4"}},{"id":3572551,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":71219,"kind":"organization","name":"10X Fund, L.P.","position":1,"cik":"0001453356","reported_name":"10X Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71220,"kind":"organization","name":"10X Capital Management, LLC","position":2,"cik":"0001457247","reported_name":"10X Capital Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"General Partner"}},{"id":71221,"kind":"person","name":"CZIRR JAMES C","position":3,"cik":"0001260641","reported_name":"CZIRR JAMES C","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Managing Member of GP"}}],"security":"Series B-2 Preferred Stock","published_at":"2019-04-01T21:59:32.000Z","date":"2019-01-11","kind":"exercise","acquired":false,"shares":167500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-6."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Conversion of Series B-1, B-2 and B-3 Convertible Preferred Stock into Common Stock. The Series B-1, B-2 and B-3 Convertible Preferred Stock was convertible at any time at the option of the holder, and was perpetual."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":3,"underlying":"Common Stock","underlying_shares":111667},"source":{"system":"sec-edgar","filing":"0001493152-19-004630","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000149315219004630/ownership.xml","form_type":"4"}}],"next_cursor":"2019-04-01T21:59:32.000000Z,3572551"}